Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 04-2013 | 03-2013 | 01-2013 | 12-2012 | 10-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2 | N/A | 0 | 5 | N/A |
| Depreciation Amortization | 5 | 1 | 1 | 0 | N/A |
| Accounts receivable | -25 | N/A | -15 | N/A | N/A |
| Other Working Capital | -21 | -10 | -13 | -3 | N/A |
| Other Operating Activity | 25 | 0 | 15 | 0 | 0 |
| Operating Cash Flow | $-14 | $-9 | $-13 | $2 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -49 | -40 | -48 | 0 | N/A |
| Investing Cash Flow | $-49 | $-40 | $-48 | $0 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 32 | N/A | N/A |
| Debt Issued | 32 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 25 | N/A | 25 | N/A | N/A |
| Other Financing Activity | 10 | 50 | 0 | 10 | 0 |
| Financing Cash Flow | $66 | $50 | $57 | $10 | $N/A |
| Beginning Cash Position | 26 | N/A | 26 | 10 | N/A |
| End Cash Position | 30 | N/A | 23 | 20 | N/A |
| Net Cash Flow | $3 | $1 | $-3 | $10 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -14 | -9 | -13 | 2 | N/A |
| Capital Expenditure | -49 | N/A | -48 | N/A | N/A |
| Free Cash Flow | -63 | -9 | -60 | 2 | 0 |